Alfonso García-Fadrique1, Rafael Estevan Estevan2, Luis Sabater Ortí3. 1. Valencian Institute of Oncology, General and Gastrointestinal Surgery, Valencia, Spain. agarciafadrique@gmail.com. 2. Valencian Institute of Oncology, General and Gastrointestinal Surgery, Valencia, Spain. 3. Hospital Clínico Universitario, Department of Surgery, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
Abstract
BACKGROUND: The standardization of surgical outcomes throughout surgical procedures is mandatory. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) should provide proficient oncological and surgical outcomes. STUDY DESIGN: The aim of this study was to identify clinically relevant quality indicators and their quality standard, and to determine their acceptable quality limit. A systematic review on cytoreductive results from 2000 to 2018 was performed focusing on clinical guidelines, consensus conferences, and publications. After the selection of quality indicators, a systematic review of indexed references was performed in order to calculate the quality standard for each indicator. STUDY SELECTION: Unicentric/multicentric series, comparative studies, and clinical trials. Studies were to include outcomes after cytoreduction of colorectal origin and series with more than 50 patients. Quality indicators with at least 10 series were mandatory and objective measurements were also mandatory for inclusion. MAIN OUTCOME MEASUREMENTS: Quality indicators selected were 1- to 5-year survival, overall disease-free survival, 1- to 5-year disease-free survival, complete surgical resection, duration of surgery, length of stay, overall morbimortality, major morbidity, re-intervention, postoperative hemorrhage, intestinal fistula, anastomotic leakage, wound infection, postoperative medical complications, overall recurrence, and failure to rescue. RESULTS: The most relevant quality indicators and critical quality limits were overall disease-free survival and 5-year overall disease-free survival (14 months and <10 months, and 14% and <4%, respectively), completeness of surgical resection (89% and <80%, respectively), overall mortality (3% and >8%, respectively), overall morbidity (47% and >63%, respectively), failure to rescue (12% and <30%, respectively), reintervention (13 and <22%, respectively), anastomotic leakage (6% and <13%, respectively), and overall recurrence (60% and <74%, respectively). CONCLUSION: This is the first study to assess quality standards in CRS + HIPEC for colorectal peritoneal metastases. The current data are of particular relevance for future studies to control the variability of this surgery.
BACKGROUND: The standardization of surgical outcomes throughout surgical procedures is mandatory. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) should provide proficient oncological and surgical outcomes. STUDY DESIGN: The aim of this study was to identify clinically relevant quality indicators and their quality standard, and to determine their acceptable quality limit. A systematic review on cytoreductive results from 2000 to 2018 was performed focusing on clinical guidelines, consensus conferences, and publications. After the selection of quality indicators, a systematic review of indexed references was performed in order to calculate the quality standard for each indicator. STUDY SELECTION: Unicentric/multicentric series, comparative studies, and clinical trials. Studies were to include outcomes after cytoreduction of colorectal origin and series with more than 50 patients. Quality indicators with at least 10 series were mandatory and objective measurements were also mandatory for inclusion. MAIN OUTCOME MEASUREMENTS: Quality indicators selected were 1- to 5-year survival, overall disease-free survival, 1- to 5-year disease-free survival, complete surgical resection, duration of surgery, length of stay, overall morbimortality, major morbidity, re-intervention, postoperative hemorrhage, intestinal fistula, anastomotic leakage, wound infection, postoperative medical complications, overall recurrence, and failure to rescue. RESULTS: The most relevant quality indicators and critical quality limits were overall disease-free survival and 5-year overall disease-free survival (14 months and <10 months, and 14% and <4%, respectively), completeness of surgical resection (89% and <80%, respectively), overall mortality (3% and >8%, respectively), overall morbidity (47% and >63%, respectively), failure to rescue (12% and <30%, respectively), reintervention (13 and <22%, respectively), anastomotic leakage (6% and <13%, respectively), and overall recurrence (60% and <74%, respectively). CONCLUSION: This is the first study to assess quality standards in CRS + HIPEC for colorectal peritoneal metastases. The current data are of particular relevance for future studies to control the variability of this surgery.
Authors: Sabine Stordeur; France Vrijens; Stephan Devriese; Koen Beirens; Elizabeth Van Eycken; Joan Vlayen Journal: Breast Date: 2011-11-06 Impact factor: 4.380
Authors: Luis Sabater; Alvaro García-Granero; Javier Escrig-Sos; Maria Del Carmen Gómez-Mateo; Juan Sastre; Antonio Ferrández; Joaquín Ortega Journal: Ann Surg Oncol Date: 2014-01-06 Impact factor: 5.344
Authors: P Dubé; L Sideris; C Law; L Mack; E Haase; C Giacomantonio; A Govindarajan; M K Krzyzanowska; P Major; Y McConnell; W Temple; R Younan; J A McCart Journal: Curr Oncol Date: 2015-04 Impact factor: 3.677
Authors: Johan L Dikken; Jurriën Stiekema; Cornelis J H van de Velde; Marcel Verheij; Annemieke Cats; Michel W J M Wouters; Johanna W van Sandick Journal: Ann Surg Oncol Date: 2012-10-09 Impact factor: 5.344
Authors: Joan Vlayen; France Vrijens; Stephan Devriese; Koen Beirens; Elizabeth Van Eycken; Sabine Stordeur Journal: Eur J Cancer Date: 2011-11-19 Impact factor: 9.162
Authors: E F W Courrech Staal; M W J M Wouters; H Boot; R A E M Tollenaar; J W van Sandick Journal: Eur J Surg Oncol Date: 2010-09-16 Impact factor: 4.424
Authors: Jenny Neuburger; Kate Walker; Chris Sherlaw-Johnson; Jan van der Meulen; David A Cromwell Journal: BMJ Qual Saf Date: 2017-09-25 Impact factor: 7.035